Skip to main content
Top
Published in: BMC Cancer 1/2016

Open Access 01-12-2016 | Research article

Quality of life after cancer—How the extent of impairment is influenced by patient characteristics

Authors: Elisabeth Peters, Laura Mendoza Schulz, Monika Reuss-Borst

Published in: BMC Cancer | Issue 1/2016

Login to get access

Abstract

Background

Although this effect is well known, tailored treatment methods have not yet been broadly adopted. The aim of this study was to identify those patient characteristics that most influence the impairment of quality of life and thus to identify those patients who need and can benefit most from specific intervention treatment.

Methods

1879 cancer patients were given the EORTC QLQ C-30 questionnaire at the beginning and end of their inpatient rehabilitation. Patients’ scores were compared to those of 2081 healthy adults (Schwarz and Hinz, Eur J Cancer 37:1345–1351, 2001). Furthermore, differences in quality of life corresponding to sex, age, tumor site, TNM stage, interval between diagnosis and rehabilitation, and therapy method were examined.

Results

Compared to the healthy population, the study group showed a decreased quality of life in all analyzed domains. This difference diminished with increasing age. Women reported a lower quality of life then men in general. Patients with prostate cancer showed the least impairment in several domains. Patients having undergone chemotherapy as well as radiotherapy were impaired the most. Surprisingly, TNM stage and interval between diagnosis and rehabilitation did not significantly influence quality of life. Global quality of life and all functional domains significantly improved after a 3-week rehabilitation program.

Conclusions

Despite an individualized and increasingly better tolerable therapy, the quality of life of cancer patients is still considerably impaired. However, systematic screening of psychosocial aspects of cancer, e.g. quality of life, could enable improved intervention.
Literature
1.
go back to reference Koch L, Jansen L, Herrmann A, Stegmaier C, Holleczek B, Singer S, et al. Quality of life in long-term breast cancer survivors - a 10-year longitudinal population-based study. Acta Oncol. 2013;52:1119–28.CrossRefPubMed Koch L, Jansen L, Herrmann A, Stegmaier C, Holleczek B, Singer S, et al. Quality of life in long-term breast cancer survivors - a 10-year longitudinal population-based study. Acta Oncol. 2013;52:1119–28.CrossRefPubMed
2.
go back to reference Waldmann A, Pritzkuleit R, Raspe H, Katalinic A. The OVIS study: health related quality of life measured by the EORTC QLQ-C30 and -BR23 in German female patients with breast cancer from Schleswig-Holstein 2007. Qual Life Res. 2007;16:767–76.CrossRefPubMed Waldmann A, Pritzkuleit R, Raspe H, Katalinic A. The OVIS study: health related quality of life measured by the EORTC QLQ-C30 and -BR23 in German female patients with breast cancer from Schleswig-Holstein 2007. Qual Life Res. 2007;16:767–76.CrossRefPubMed
5.
go back to reference Borneman T, Piper BF, Koczywas M, Munevar CM, Sun V, Uman GC, et al. A qualitative analysis of cancer-related fatigue in ambulatory oncology. Clin J Oncol Nurs. 2012;16:E26–32.CrossRefPubMed Borneman T, Piper BF, Koczywas M, Munevar CM, Sun V, Uman GC, et al. A qualitative analysis of cancer-related fatigue in ambulatory oncology. Clin J Oncol Nurs. 2012;16:E26–32.CrossRefPubMed
6.
go back to reference Cella D, Davis K, Breitbart W, Curt G. Cancer-Related Fatigue: Prevalence of Proposed Diagnostic Criteria in a United States Sample of Cancer Survivors. J Clin Oncol. 2001;19:3385–91.PubMed Cella D, Davis K, Breitbart W, Curt G. Cancer-Related Fatigue: Prevalence of Proposed Diagnostic Criteria in a United States Sample of Cancer Survivors. J Clin Oncol. 2001;19:3385–91.PubMed
7.
go back to reference Curt GA, Breitbart W, Cella D, Groopman JE, Horning SJ, Itri LM, et al. Impact of Cancer-Related Fatigue on the Lives of Patients: New Findings From the Fatigue Coalition. Oncologist. 2000;5:353–60.CrossRefPubMed Curt GA, Breitbart W, Cella D, Groopman JE, Horning SJ, Itri LM, et al. Impact of Cancer-Related Fatigue on the Lives of Patients: New Findings From the Fatigue Coalition. Oncologist. 2000;5:353–60.CrossRefPubMed
8.
go back to reference Hofman M, Ryan JL, Figueroa-Moseley CD, Jean-Pierre P, Morrow GR. Cancer-Related Fatigue: The Scale of the Problem. Oncologist. 2007;12:4–10.CrossRefPubMed Hofman M, Ryan JL, Figueroa-Moseley CD, Jean-Pierre P, Morrow GR. Cancer-Related Fatigue: The Scale of the Problem. Oncologist. 2007;12:4–10.CrossRefPubMed
9.
go back to reference Stasi R, Abriani L, Beccaglia P, Terzoli E, Amadori S. Cancer-related fatigue. Cancer. 2003;98:1786–801.CrossRefPubMed Stasi R, Abriani L, Beccaglia P, Terzoli E, Amadori S. Cancer-related fatigue. Cancer. 2003;98:1786–801.CrossRefPubMed
11.
go back to reference Coates A, Thomson D, McLeod GR, Hersey P, Gill PG, Olver IN, et al. Prognostic value of quality of life scores in a trial of chemotherapy with or without interferon in patients with metastatic malignant melanoma. Eur J Cancer. 1993;29A:1731–4.CrossRefPubMed Coates A, Thomson D, McLeod GR, Hersey P, Gill PG, Olver IN, et al. Prognostic value of quality of life scores in a trial of chemotherapy with or without interferon in patients with metastatic malignant melanoma. Eur J Cancer. 1993;29A:1731–4.CrossRefPubMed
12.
go back to reference Gotay CC, Kawamoto CT, Bottomley A, Efficace F. The prognostic significance of patient-reported outcomes in cancer clinical trials. J Clin Oncol. 2008;26:1355–63.CrossRefPubMed Gotay CC, Kawamoto CT, Bottomley A, Efficace F. The prognostic significance of patient-reported outcomes in cancer clinical trials. J Clin Oncol. 2008;26:1355–63.CrossRefPubMed
13.
go back to reference Maisey N, Norman A, Watson M, Allen M, Hill M, Cunningham D. Baseline quality of life predicts survival in patients with advanced colorectal cancer. Eur J Cancer. 2002;38:1351–7.CrossRefPubMed Maisey N, Norman A, Watson M, Allen M, Hill M, Cunningham D. Baseline quality of life predicts survival in patients with advanced colorectal cancer. Eur J Cancer. 2002;38:1351–7.CrossRefPubMed
14.
go back to reference Michael M, Tannock IF. Measuring health-related quality of life in clinical trials that evaluate the role of chemotherapy in cancer treatment. CMAJ. 1998;158:1727–34.PubMedPubMedCentral Michael M, Tannock IF. Measuring health-related quality of life in clinical trials that evaluate the role of chemotherapy in cancer treatment. CMAJ. 1998;158:1727–34.PubMedPubMedCentral
15.
go back to reference Fayers PM, Aaronson NK, Bjordal K, Groenvold M, Curran D, Bottonley A, on behalf of the EORTC Quality of Life Group. The EORTC QLQ-C30 Scoring Manual (3rd edition). Brussels: European Organisation for Research and Treatment of Cancer; 2001. Fayers PM, Aaronson NK, Bjordal K, Groenvold M, Curran D, Bottonley A, on behalf of the EORTC Quality of Life Group. The EORTC QLQ-C30 Scoring Manual (3rd edition). Brussels: European Organisation for Research and Treatment of Cancer; 2001.
16.
go back to reference Schwarz R, Hinz A. Reference data for the quality of life questionnaire EORTC QLQ-C30 in the general German population. Eur J Cancer. 2001;37:1345–51.CrossRefPubMed Schwarz R, Hinz A. Reference data for the quality of life questionnaire EORTC QLQ-C30 in the general German population. Eur J Cancer. 2001;37:1345–51.CrossRefPubMed
17.
go back to reference Osoba D, Rodrigues G, Myles J, Zee B, Pater J. Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol. 1998;16:139–44.PubMed Osoba D, Rodrigues G, Myles J, Zee B, Pater J. Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol. 1998;16:139–44.PubMed
18.
go back to reference R Development Core Team. R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing. Wien, Österreich 2009. http://www.R-project.org. Accessed 25 February 2015. R Development Core Team. R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing. Wien, Österreich 2009. http://​www.​R-project.​org. Accessed 25 February 2015.
19.
go back to reference Repetto L. Greater risks of chemotherapy toxicity in elderly patients with cancer. J Support Oncol. 2003;1:18–24.PubMed Repetto L. Greater risks of chemotherapy toxicity in elderly patients with cancer. J Support Oncol. 2003;1:18–24.PubMed
20.
go back to reference Gomez-Millan J. Radiation therapy in the elderly: more side effects and complications? Crit Rev Oncol Hematol. 2009;71:70–8.CrossRefPubMed Gomez-Millan J. Radiation therapy in the elderly: more side effects and complications? Crit Rev Oncol Hematol. 2009;71:70–8.CrossRefPubMed
21.
go back to reference Zack MM. Health-Related Quality of Life—United States, 2006 and 2010. MMWR. 2013;62(03):105–11. Zack MM. Health-Related Quality of Life—United States, 2006 and 2010. MMWR. 2013;62(03):105–11.
22.
go back to reference Romer G. Kinder körperlich kranker Eltern: Psychische Belastungen, Wege der Bewältigung und Perspektiven der seelischen Gesundheitsvorsorge. Prax Kinderpsychol Kinderpsychiatr. 2007;56(10):870–90.CrossRefPubMed Romer G. Kinder körperlich kranker Eltern: Psychische Belastungen, Wege der Bewältigung und Perspektiven der seelischen Gesundheitsvorsorge. Prax Kinderpsychol Kinderpsychiatr. 2007;56(10):870–90.CrossRefPubMed
23.
go back to reference Hauken MA, Holsen I, Fismen E, Larsen T. Working toward a good life as a cancer survivor. Cancer Nurs. 2015;38:3–14.CrossRefPubMed Hauken MA, Holsen I, Fismen E, Larsen T. Working toward a good life as a cancer survivor. Cancer Nurs. 2015;38:3–14.CrossRefPubMed
24.
go back to reference McCabe RM, Grutsch JF, Nutakki SB, Braun DP, Markman M. Can Quality of Life Assessments Differentiate Heterogeneous Cancer Patients? Plos One. 2014;9(6):e99445.CrossRefPubMedPubMedCentral McCabe RM, Grutsch JF, Nutakki SB, Braun DP, Markman M. Can Quality of Life Assessments Differentiate Heterogeneous Cancer Patients? Plos One. 2014;9(6):e99445.CrossRefPubMedPubMedCentral
27.
go back to reference Brown DJF, Mcmillan DC, Milroy R. The correlation between fatigue, physical function, the systemic inflammatory response, and psychological distress in patients with advanced lung cancer. Cancer. 2005;103:377–82.CrossRefPubMed Brown DJF, Mcmillan DC, Milroy R. The correlation between fatigue, physical function, the systemic inflammatory response, and psychological distress in patients with advanced lung cancer. Cancer. 2005;103:377–82.CrossRefPubMed
28.
go back to reference Mallinson T, Cella D, Cashy J, Holzner B. Giving Meaning to Measure: Linking Self-Reported Fatigue and Function to Performance of Everyday Activities. J Pain Symptom Manage. 2006;31:229–41.CrossRefPubMed Mallinson T, Cella D, Cashy J, Holzner B. Giving Meaning to Measure: Linking Self-Reported Fatigue and Function to Performance of Everyday Activities. J Pain Symptom Manage. 2006;31:229–41.CrossRefPubMed
30.
go back to reference Hamidou Z, Dabakuyo TS, Bonnetain F. Impact of response shift on longitudinal quality-of-life assessment in cancer clinical trials. Expert Rev Pharmacoecon Outcomes Res. 2011;11(5):549–59.CrossRefPubMed Hamidou Z, Dabakuyo TS, Bonnetain F. Impact of response shift on longitudinal quality-of-life assessment in cancer clinical trials. Expert Rev Pharmacoecon Outcomes Res. 2011;11(5):549–59.CrossRefPubMed
31.
go back to reference Mehnert A, Koch A. Psychological comorbidity and health-related quality of life and its association with awareness, utilization, and need for psychosocial support in a cancer register-based sample of long-term breast cancer survivors. J Psychosom Res. 2008;64:383–91.CrossRefPubMed Mehnert A, Koch A. Psychological comorbidity and health-related quality of life and its association with awareness, utilization, and need for psychosocial support in a cancer register-based sample of long-term breast cancer survivors. J Psychosom Res. 2008;64:383–91.CrossRefPubMed
32.
go back to reference Wikman A, Djärv T, Johar A, Lagergren P. Health-related quality of life does not differ between short-term, long-term and very long-term cancer survivors in the Swedish general population. Psychooncology. 2013;22:1369–74.CrossRefPubMed Wikman A, Djärv T, Johar A, Lagergren P. Health-related quality of life does not differ between short-term, long-term and very long-term cancer survivors in the Swedish general population. Psychooncology. 2013;22:1369–74.CrossRefPubMed
33.
go back to reference Dimeo FC, Stieglitz RD, Novelli-Fischer U, Fetscher S, Keul J. Effects of physical activity on the fatigue and psychologic status of cancer patients during chemotherapy. Cancer. 1999;85:2273–7.CrossRefPubMed Dimeo FC, Stieglitz RD, Novelli-Fischer U, Fetscher S, Keul J. Effects of physical activity on the fatigue and psychologic status of cancer patients during chemotherapy. Cancer. 1999;85:2273–7.CrossRefPubMed
34.
go back to reference Mock V, Pickett M, Ropka ME, Lin EM, Stewart KJ, Rhodes VA, et al. Fatigue and Quality of Life Outcomes of Exercise During Cancer Treatment. Cancer Pract. 2001;9:119–27.CrossRefPubMed Mock V, Pickett M, Ropka ME, Lin EM, Stewart KJ, Rhodes VA, et al. Fatigue and Quality of Life Outcomes of Exercise During Cancer Treatment. Cancer Pract. 2001;9:119–27.CrossRefPubMed
35.
go back to reference Schwartz AL. Daily Fatigue Patterns and Effect of Exercise in Women with Breast Cancer. Cancer Pract. 2000;8:16–24.CrossRefPubMed Schwartz AL. Daily Fatigue Patterns and Effect of Exercise in Women with Breast Cancer. Cancer Pract. 2000;8:16–24.CrossRefPubMed
36.
go back to reference Silver JK, Baima J, Mayer S. Impairment-Driven Cancer Rehabiliation: An essential component of quality care and survivorship. CA Cancer J Clin. 2013;63:295–317.CrossRefPubMed Silver JK, Baima J, Mayer S. Impairment-Driven Cancer Rehabiliation: An essential component of quality care and survivorship. CA Cancer J Clin. 2013;63:295–317.CrossRefPubMed
Metadata
Title
Quality of life after cancer—How the extent of impairment is influenced by patient characteristics
Authors
Elisabeth Peters
Laura Mendoza Schulz
Monika Reuss-Borst
Publication date
01-12-2016
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2016
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-016-2822-z

Other articles of this Issue 1/2016

BMC Cancer 1/2016 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine